Condition: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) · Relapsed/Refractory Non-Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma (DLBCL) · Sponsor: Health Institutes of Turkey
The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed/refractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers. This therapy is based on collecting the patient's own T cells, genetically modifying them in a laboratory to recognize the CD19 antigen, and reinfusing them into the patient. The goal is to target leukemia or lymphoma cells and achieve disease control. The primary objective is to assess the overall response rate at Day 28 after infusion and to evaluate the safety profile of the treatment. Secondary objectives include assessment of complete response rate, duration of response, overall survival, and progression-free survival, as well as the frequency and severity of cytokine release syndrome (CRS), neurotoxicity (ICANS), and other treatment-related adverse events. In addition, the in vivo persistence and immunological effects of CAR-T cells will be evaluated. Eligible patients must be 18 years of age or older, have an adequate performance status, sufficient organ function, and meet disease-specific eligibility criteria. Key exclusion criteria include active severe infection, uncontrolled cardiac disease, activ…
This description comes directly from the study's public registry record.
Funda Ceran Ankara Bilkent City Hospital - Hematology Clinic, Prof. MD · +90 (312) 552 60 00 · ceranf@gmail.com
Şule Mine Bakanay Öztürk Ankara Bilkent City Hospital - Hematology Clinic, Prof. MD · +90 (312) 552 60 00 · sulemine.ozturk@yahoo.com
Always discuss trial participation with your own doctor first.
| Ankara Bilkent City Hospital - Hematology Clinic | Ankara, Turkey (Türkiye) | Recruiting |
| Ankara Etlik City Hospital - Hematology Clinic | Ankara, Turkey (Türkiye) | Recruiting |
| Hacettepe University Faculty of Medicine - Department of Internal Medicine, Division of Hematology | Ankara, Turkey (Türkiye) | Not Yet Recruiting |
| University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital | Ankara, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07502118